PLEASANTON, Calif., Jan. 18, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 350 companies are using Veeva training solutions to modernize employee qualification processes. A growing number of biopharmas are adopting end-to-end learning management for advanced employee education and compliance.
"Veeva is helping us streamline GxP training to speed employee qualification and onboarding as we grow," said Debra Sawyer, vice president of quality assurance at PepGen. "Implementing Veeva Vault Training and Veeva LearnGxP improved our efficiency and fostered a more engaging training environment, supporting our commitment to quality excellence and compliance."
With Veeva Vault QualityDocs, Veeva Vault Training, and Veeva LearnGxP, companies can advance their GxP training programs to prevent quality deficiencies, job-related errors, and audit failures. Using a complete, validated solution for GxP training, content management, and accredited eLearning courses enables companies to design impactful training programs that improve job performance and ensure inspection readiness.
"With Veeva Vault Training and Veeva LearnGxP, we can develop end-to-end training programs, assign them to employees, and track progress all in one place," said Grace DaFonseca, quality operations manager at Cerevel. "Partnering with a technology provider that has deep life sciences expertise helps us address complex GxP training issues, improving compliance and efficiency."
"Veeva is addressing an industrywide challenge by helping companies more effectively qualify job readiness while increasing visibility and compliance," said Kent Malmros, vice president, Veeva training strategy. "We're empowering customers with one comprehensive solution to optimize life sciences training and streamline employee education."
To learn more about Veeva's training solutions, visit veeva.com/VeevaTrainingSolutions.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2023, which you can find here (a summary of risks which may impact our business can be found on pages 38 and 39), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$210.63 |
Daily Change: | 0.74 0.35 |
Daily Volume: | 1,135,895 |
Market Cap: | US$34.110B |
November 20, 2024 November 19, 2024 October 24, 2024 September 05, 2024 September 05, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB